AAC
Home Help [Feedback] [For Subscribers] [Archive] [Search] --
AAC Accepts, published online ahead of print on 24 March 2008
This Article
Right arrow Full Text (PDF)
Right arrow Other Versions of this Article:
AAC.01620-07v1
52/6/2279    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by SMITH, K.
Right arrow Articles by LOCIURO, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by SMITH, K.
Right arrow Articles by LOCIURO, S.

 Previous Article  |  Next Article 

Antimicrob. Agents Chemother. doi:10.1128/AAC.01620-07
Copyright (c) 2008, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights Reserved.

ANTISTREPTOCOCCAL ACTIVITY OF AR-709, COMPARED TO OTHER AGENTS

KATHY SMITH, LOIS M. EDNIE, PETER C. APPELBAUM*, STEPHEN HAWSER, and SERGIO LOCIURO

Department of Pathology, Hershey Medical Center, Hershey, PA 17033; and Arpida AG, Reinach, Switzerland

* To whom correspondence should be addressed. Email: pappelbaum{at}psu.edu.


  Abstract

Against 300 strains of pneumococci and 100 group A streptococci of differing {beta}-lactam, macrolide, and quinolone resistance phenotypes, AR-709 was very active with all MICs ≤2 µg/ml. Furthermore, AR-709 was active against strains that were both susceptible and resistant to trimethoprim-sulfamethoxazole.






Home Help [Feedback] [For Subscribers] [Archive] [Search] --
Clin. Vaccine Immunol. Clin. Microbiol. Rev.
J. Clin. Microbiol. ALL ASM JOURNALS

Copyright © 2008 by the American Society for Microbiology. All rights reserved.